i
i
Up-to-date Information
Up-to-Date Info: To find the latest CDC information on this topic go to: https://www.cdc.gov/coronavirus/2019-nCoV/index.html
Interim considerations : Preparing for the potential management of anaphylaxis after COVID-19 vaccination
-
March 3, 2021
Details:
-
Corporate Authors:
-
Description:Anaphylaxis, an acute and potentially life-threatening allergic reaction, has been reported rarely following COVID-19 vaccination. These interim considerations provide recommendations on assessment and management of anaphylaxis following COVID-19 vaccination. Detailed information on CDC recommendations for vaccination, including contraindications and precautions to vaccination, can be found in the Clinical Considerations for Use of COVID-19 Vaccines Currently Authorized in the United States. Patients should be screened prior to receipt of each vaccine dose, and those with a contraindication should not be vaccinated. A COVID-19 prevaccination questionnaire is available to assist with screening.
-
Content Notes:Overview -- Personnel, medications, and supplies for assessing and managing anaphylaxis -- Routine observation periods following COVID-19 vaccination -- Early recognition of anaphylaxis -- Management of anaphylaxis at a COVID-19 vaccination location -- Considerations for anaphylaxis management in special populations -- Patient counseling -- Reporting anaphylaxis -- Additional resources -- References -- Previous Updates.
-
Subjects:
-
Document Type:
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type: